Peloruside A (PLA) and laulimalide (LAU) are potent microtubule-stabilizing natural products with a mechanism of action similar to that of paclitaxel. However, the binding site of PLA and LAU on tubulin remains poorly understood. Drug resistance in anticancer treatment is a serious problem. We developed LAU-and PLA-resistant cell lines by selecting 1A9 human ovarian carcinoma cells able to grow in the presence of one of these agents. 1A9-LAU resistant cells (L4) were 39-fold resistant to the selecting agent and 39-fold cross-resistant to PLA; whereas, the 1A9-PLA resistant cells (R1) were 6-fold resistant to the selecting agent while they remained sensitive to LAU. Neither cell line showed resistance to paclitaxel or other drugs that bind to the taxoid site on ȕ-tubulin, nor was there resistance to microtubule-destabilizing drugs.
Introduction
Microtubules are major cytoskeletal polymers comprised of heterodimers of Į-and ȕ-tubulin subunits (1) . They are vital for several cellular functions, including mitosis, intracellular trafficking, and maintenance of cell shape. The importance of microtubules in mitotic spindle Ͷ microtubule-destabilizing factors (12) , and changes in the drugs' target molecule, tubulin (13) (14) (15) . Tubulin alterations include tubulin mutations (14) , altered expression of ȕ-tubulin isotypes (13, 15) , and increased microtubule dynamics (16) . Since PLA and LAU are poor substrates for the Pgp drug efflux pump (6, 7) , resistance to these compounds is unlikely to be dependent on development of a multidrug-resistant (MDR) phenotype.
Several cellular studies have indicated a role for ȕI-tubulin mutations in the development of resistance to PTX and other taxoid-site microtubule-stabilizing agents (13, 14, (17) (18) (19) .
Mutations at the taxoid binding site on ȕI-tubulin impair drug-tubulin interactions (17) ; however, the clinical occurrence of such ȕ-tubulin mutations in drug-resistant cancer patients seems to be rare, although it has yet to be thoroughly investigated in patients with acquired resistance (20, 21) . Differential expression of specific ȕ-tubulin isotypes has also been associated with resistance to microtubule-targeting agents in cell lines and in patients (13, 15) . The aim of this study was, therefore, to generate cell lines resistant to PLA and LAU and to determine the mechanisms of resistance by testing for tubulin mutations and changes in tubulin isotype expression.
Materials and Methods

Drugs
Natural peloruside A (PLA) and laulimalide (LAU) were isolated and purified from the marine sponges Mycale hentscheli (New Zealand) and Cacospongia mycofijiensis (Tonga), respectively, and stored as 1 mM stock solutions in absolute ethanol at -80 ºC. Synthetic LAU was a gift from Arun Ghosh, Purdue University, and synthetic discodermolide (DISC) was a gift from Ian Paterson, University of Cambridge, UK. Paclitaxel (PTX), epothilone A (EPOA), vinblastine (VBL), vincristine (VCR), and colchicine (COL) were purchased from Sigma Chemical Co. (St. Louis, MO). Epothilone B (EPOB) was from Novartis Pharmaceuticals Corp. ͷ (East Hanover, NJ), and 2-methoxy-estradiol (2ME2) was from Sigma or EntreMed, Inc (Rockville, MD).
Cell culture
The human ovarian carcinoma cell line 1A9, a derivative of the A2780 cell line, was obtained from the NIH (17) . Cells were cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen), 0.25 units/mL insulin (Sigma), 100 units/mL pencillin and 100 units/mL streptomycin (Invitrogen). The cells were maintained at 37 °C in a humidified air atmosphere containing 5% CO 2 .
Generation of LAU-and PLA-resistant cell lines.
A LAU resistant cell line 1A9-L4 (L4) was obtained by exposing 1A9 cells to increasing concentrations of LAU (10-150 nM) over a period of 18 months. The L4 cells that grew in the presence of 150 nM LAU exhibited the greatest resistance and were selected for further analysis.
The stability of the resistant phenotype in L4 cells was assessed by incubating the cells in the presence of drug-free medium for more than 6 months with no reduction in the relative resistance to LAU.
A PLA-resistant cell line 1A9-R1 (R1) was derived from 1A9 human ovarian cancer cells grown for a number of months in medium with PLA at a concentration just above the IC 50 (25 nM). Verapamil (10 ȝM) was included throughout to prevent selection of cells with the MDR phenotype, since PLA has been shown to be a substrate, although a poor one, for the Pgp pump (6) . Over a period of six months, the concentration of PLA was gradually increased in steps to 30, 40, 50, 60, 80, 100 and 150 nM. The cells were typically exposed to each dose of PLA for 3-5 days, and then allowed to recover in drug-free medium. Once confluent, cells were treated with the next highest concentration of PLA until cells were able to grow at the higher PLA concentrations. The cells were then cloned to ensure the resistant cell stocks were homogeneous.
The resistant phenotype in R1 cells was stable in drug-free medium with no reduction in the relative resistance to PLA observed over many months and passages.
Cell proliferation assay
To determine the IC 50 for growth inhibition, we used either a sulforhodamine B protein staining assay or an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay as previously described (5, 17) . IC 50 values of the resistant cell lines were always compared to parental 1A9 cells in the same (paired) experiment. Cells were tested for resistance against LAU, PLA, and three taxoid-binding site drugs (PTX, EPOA, and DISC), and three microtubule-destabilizing agents (VLB, COL, and 2ME).
Analysis of drug effects on tubulin polymerization and function
Intracellular polymerization of tubulin. Drug-induced tubulin polymerization in cells was measured by SDS-PAGE electrophoresis of soluble and pelleted fractions from centrifuged cell lysates (14,400 g for 10 min) and immunoblotting for tubulin. Cells were treated with different concentrations of PLA or LAU for 16 h, then processed as previously described (17) .
For L4 cells, mouse monoclonal Į-tubulin primary antibody (1:1000, Sigma) was used in conjunction with an anti-mouse Alexa Fluor 680 secondary antibody (Invitrogen).
Immunoreactivity was detected in a LI-COR Odyssey Infrared Imaging System (LI-COR Biosciences) and quantified by densitometry with ImageJ (NIH). For Western blotting of R1 cells, a rabbit polyclonal primary antibody to Į-tubulin (1:1000, Abcam) was used with a Cy5-conjugated goat anti-rabbit secondary antibody (1:2500, Amersham). The electrophoresed proteins were transferred to an Immobilon FL membrane (Millipore Corp), and fluorescence was measured using a Fujifilm FLA-5100 imaging system (Fuji Photo Film Co.). The percentage of polymerized tubulin was calculated from the band densities of soluble and pelleted tubulin.
Immunocytochemistry and confocal microscopy. Immunocytochemistry and confocal microscopy of the 1A9, L4 and R1 cells was performed as previously described (22, 23) .
Cell cycle analysis. Cell cycle analysis was performed by flow cytometry following staining of the DNA with propidium iodide as previously described (5).
Analysis of tubulin structural alterations and isotype expression patterns
Sequence analysis of human Į-and ȕ-tubulin genes. Total RNA was isolated from the cells using a Qiagen RNeasy kit, and RT-PCR was performed using a Protoscript First Strand cDNA synthesis kit (New England Biolabs). PCR-amplified cDNA of ȕI-tubulin (HM40/TUBB gene, RNA accession # NM_178014) was performed using the following primers purchased from Invitrogen:
PCR products were then direct sequenced using the following seven primers: Subcloning of the cDNA PCR-amplified products was performed using the TOPO TA cloning system (Invitrogen), followed by direct sequencing with the primers listed above. A minimum of 20 clones was analyzed for each sample. All PCR reactions were performed in 50 μL reaction mixtures, as previously described (24) . Multiple sequence alignment of ȕ-tubulin isotypes was performed using the Clustal W method and the MegAlign program (Lasergene, ͺ DNASTAR). All Į-tubulin primer sequences for the predominant Į-tubulin isotype (KĮ1) were obtained from Poruchynsky et al. (25) . Primers were purchased from Invitrogen.
Quantitative real-time polymerase chain reaction. Expression levels of the seven ȕ-tubulin isotypes and a house-keeping gene mRNAs were determined using a quantitative SYBR green PCR method. Several common house-keeping genes were tested, but only 18S rRNA showed similar expression in the parental and the resistant cells. Total RNA was extracted from frozen cells using an RNeasy® Protect Cell Mini kit (Qiagen) following the manufacturer's instructions. Extracted total RNA (1 ȝg) was treated with DNase I (amplification grade, Invitrogen) to remove any genomic DNA, and cDNA was synthesized using SuperScript™ III First-Strand Synthesis Supermix (Invitrogen) in accordance with the manufacturer's instructions.
Excluding a previously described primer set for the ȕIII-tubulin gene (26) , all primers were designed using 'Beacon Designer' (PREMIER Biosoft International, Palo Alto, CA, USA) and manufactured by Invitrogen and are listed in the Supplementary Data Table S1 . For quantification of expression levels of each of the seven ȕ-tubulin isotypes, and 18S rRNA, singleplex reaction mixes were prepared containing a single set of isotype-specific or 18S rRNA Table S2 ). The primer specificity was confirmed by sequencing the PCR product. The 1A9 parental cell line was used as a control for the resistant cell lines and quantification of samples was determined by the 2 -¨¨CT method (27) .
One-dimensional gel electrophoresis and Western blotting. Cell lysates were prepared using a cell lysis buffer containing 30 mM Tris-HCl, 7 M urea, 2 M thiourea, and 4% (w/v) 3- 
6). Isoelectric focusing was performed in an Ettan IPGphor Isoelectric
Focusing Unit (GE Healthcare) with the following settings: 1.
Step and hold 300 V for 30 min; 2.
Gradient 1000 V for 30 min; 3. Gradient 5000 V for 90 min; 4.
Step and hold 5000 V for 25 min.
After the isoelectric focusing, the strips were equilibrated in equilibration buffer (50 mM Tris, 6
M urea, 30% glycerol, and 2% SDS) containing 1% DTT for 10 min, then in equilibration buffer 
Data analysis
Tests for significant differences used ANOVA or Student's t-tests. P<0.05 was taken as significant, and all data are presented as mean ± SEM.
Results
Resistance profile of L4 and R1 cells
To gain a better understanding of the specific effects and interactions of LAU and PLA with the microtubule cytoskeleton, we selected 1A9 ovarian carcinoma cells with increasing concentrations of either LAU or PLA and generated two stable resistant cell lines named L4 and R1, respectively. The ability of drugs to inhibit growth of these resistant cells is shown in Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ͳͳ 1. The L4 cell line exhibited 39-fold resistance to LAU compared to the parental 1A9 cells, but showed no significant cross-resistance to microtubule-targeting agents known to bind at the taxoid site (PTX, EPOA, EPOB), the vinca site (VLB, VCR), or the colchicine site (COL, 2ME).
L4 cells showed a slightly increased resistance to PTX and EPOA, but the magnitudes of the effects were very small and unlikely to be biologically significant. Interestingly, the L4 cells were highly cross-resistant to PLA, confirming earlier evidence that the two drugs have an identical or overlapping binding site (6) . The R1 cells were 5.6-fold resistant to PLA but remained sensitive to the other microtubule-targeting drugs tested (Table 1) . Interestingly, unlike the case of L4 cells that were resistant to both LAU and PLA, there was no significant resistance of R1 cells to LAU. This suggests that the binding site might not be identical, but overlapping, for PLA and LAU on tubulin.
Impaired drug-induced tubulin polymerization
To determine whether the drug-resistant cells displayed altered drug-tubulin interactions, we tested the ability of the drugs to induce tubulin polymerization using a cell-based assay.
Treatment of 1A9 cells with as little as 10 nM LAU resulted in near-maximum polymerization (90% P) compared to untreated cells in which no polymerized tubulin was detected (Fig. 1A) . In contrast, LAU treatment of the L4 cells had only a minimal effect at concentrations as high as 100 nM (24% P), consistent with the drug-resistant phenotype of these cells. PTX-induced polymerization in both cell lines, however, was not compromised. With PLA (Fig. 1B ) 100 nM PLA induced 61% tubulin polymerization in 1A9 cells; whereas, in L4 and R1 cells, 100 nM PLA only induced 13% and 22% polymerization, respectively. These results for LAU and PLA mirror the antiproliferative assays summarized in Table 1 . ͳʹ Using confocal microscopy, we showed that the microtubule-stabilizing effects of LAU and PLA were significantly impaired in the drug-resistant cell lines (Fig. 2) . Whereas treatment of 1A9 cells with as little as 10 nM LAU induced microtubule stabilization (bundling) ( Fig. 2A) Table S3 ). Taken together, these results corroborate and extend our cytotoxicity and cellbased tubulin polymerization assays and suggest that impaired drug-tubulin interaction mediates the resistance phenotype.
We also evaluated the ability of LAU and PLA to induce cell cycle arrest in the resistant cells (Fig. 3) . Again, we found that the resistant cells required higher concentrations of LAU and PLA, but not PTX, to obtain a given level of G 2 /M block.
Distinct tubulin mutations are identified in LAU-and PLA-resistant cell lines
The higher IC 50 values of LAU and PLA in the L4 and R1 cells prompted us to investigate whether a sequence alteration in the tubulin gene itself (13, 14) might account for the resistance of the cells. In addition, we reasoned that Pgp overexpression was an unlikely mechanism of resistance as we did not observe any significant cross-resistance to PTX, which is an excellent Pgp substrate (Table 1) . Table S4 ). In contrast, the expression levels of these genes in R1 cells were similar to that in parental cells. The mRNA expression levels of the other isotypes, ȕI (class I), ȕV (class V), and ͳͶ ȕVI (class VI), were similar in the parental and the resistant cells. We were unable to amplify ȕIVa-and ȕIVb-tubulin despite trying various primer sets and different amplification conditions for the PCR. There are two likely reasons for this problem, low mRNA abundance or nonspecific primers.
Tubulin protein levels in 1A9, L4 and R1 cells. The protein expression levels of the two ȕ-tubulin isotypes, ȕII and ȕIII, and the two microtubule subunits, Į-and ȕ-tubulin, in the parental and the resistant cells were investigated by Western blotting (Fig. 4B and C) . The total Į-and ȕ-tubulin protein levels were similar in all three cell lines, but ȕII-and ȕIII-tubulin isotype protein expression was increased by 7.4 ± 1.2 fold and 5.6 ± 0.4 fold, respectively, in the resistant L4 cells (Fig. 4C) . Conversely, ȕII-and ȕIII-tubulin isotype protein levels in R1 cells were similar to that in parental cells. The increased expression of βII and βIII isotypes in L4 cells was confirmed by immunocytochemistry ( Supplementary Data Fig. S4 ). (8) . They showed that the peptide containing amino acid ȕ296 provided a favorable binding surface for the compounds. These results (8, 31, 32) demonstrate that the above amino acid residues are necessary for the stable binding of LAU and PLA to ȕ-tubulin, but that they have no effect on taxoid-site drug binding. Therefore, a mutation in 306 (as seen in L4 cells) and 296 (as seen in R1 cells) could cause impaired druginduced tubulin polymerization and, therefore, confer resistance to the drugs. Notably, amino ͳ acid R306 seems to be of major importance for LAU and PLA binding. This might explain why the L4 cell line shows a very rare mutation event in which two point mutations have occurred at the same location in both alleles. Alternatively, however, it is possible that L4 may comprise two cell populations, one with the H306 and one with the C306 mutation. In any case, the fact that there was no wild-type 306 left suggests that indeed this residue is important for LAU binding and that the cells "had to mutate" it in order to adapt to the drug selection pressure. The fact that L4 cells are also resistant to PLA provides strong support that LAU and PLA share the same binding site. Mutation of amino acid A296 has a selective effect on PLA activity with no impact on LAU activity, but the drug-amino acid interactions have not been specifically modeled at this stage, although alanine 296, like arginine 306, is located in the proposed LAU/PLA site.
These results are the first to provide cell-based support for a ȕ-tubulin binding site of LAU and PLA. All other evidence is based on computer docking simulations and hydrogen-deuterium exchange mass spectrometry (8, 31, 32) . The clinical relevance of ȕI-tubulin mutations in drug resistance is not clear, as such mutations are rarely seen in tumors (20, 21) . This led us to search for other tubulin-related mechanisms that contribute to a cell's distinct resistance profiles to LAU and PLA.
ȕ-tubulin isotype alterations
ȕ-tubulin in humans exists as seven different isotypes: ȕI (class I), ȕII (class II), ȕIII (class III), ȕIVa (class IVa), ȕIVb (class IVb), ȕV (class V), and ȕVI (class VI) (33) . Some of these isotypes exhibit tissue-specific expression; whereas, other isotypes are constitutively expressed in all tissues (34, 35) . The present study investigated mRNA expression of five of these isotypes in the resistant L4 and R1 cells. ȕII-and ȕIII-tubulin mRNAs were found to be increased in L4 cells but not R1 cells. The protein abundance of the isotypes in the cells mirrored the mRNA 
ͳ results, but there were no significant alterations in the total ȕ-and total Į-tubulin protein levels.
Based on the qRT-PCR results, in 1A9 parental cells, βII and βIII mRNA levels were each 7% of the total mRNA (excluding βIVa/b) and in the resistant L4 cells, βII and βIII mRNA levels were increased to 55% and 19% of the total mRNA, respectively. Comparative protein levels in the cells could not be determined from the Western blots since different antibodies were used for each isotype; however, it is expected that the βI isotype will still be the predominant β-isotype in the L4 cells. Overexpression of ȕII-and ȕIII-tubulin has been reported to be a predictive marker for drug resistance in cancer patients (13, 15) . ȕIII-tubulin is a multifunctional protein, and its upregulation is associated with tumor progression and resistance to tubulin-binding and DNAdamaging agents (36, 37) . There is now a clear indication that ȕIII-tubulin plays a vital role in microtubule dynamic instability and in opposing the ability of tubulin binding agents to suppress (Fig. 5) , were in the low pH region of the isoelectric focussing, but were at a similar molecular weight (50 kDa) as the main ȕII-and ȕIII-tubulin isotypes, indicating that the additional spots were likely to be due to posttranslational modifications such as phosphorylation or glutamylation. A study by Khan et al. (40) has shown that the phosphorylation of ȕIII-tubulin can regulate microtubule assembly in vivo.
Phosphorylation of ȕIII-tubulin occurs at serine or tyrosine residues near the C-terminus (40) .
Tubulin modification at the C-terminus can affect the conformation of the tubulin protein, preventing the binding of a drug to tubulin (41) . It would be of great interest to determine the precise posttranslational modifications of ȕII-and ȕIII-tubulin in L4 cells and their contribution to the resistance phenotype.
Conclusions
Overall, our results provide the first cell-based evidence in support of a ȕ-tubulin binding site for LAU and PLA that involves R306 for both compounds and A296 for PLA. We also demonstrated that resistance to LAU and PLA may arise from altered drug-tubulin interactions as a result of not only ȕI-tubulin structural mutations but also increased ȕII-and ȕIII-tubulin isotype expression and posttranslational modification. Future directions of study will be to elucidate the functional significance of these ȕ-tubulin mutations and isotype alterations in the resistant cells. Understanding the role of multiple ȕ-tubulin alterations will help improve targeting of anticancer drugs whose mechanisms of action involve interactions with microtubules. relative to 1A9 cells. * P < 0.05; ** P < 0.01, Student's t-test. Data are the mean ± SEM (n=5 experiments). 
